Cargando…

GLP‐1 Is a Coronary Artery Vasodilator in Humans

BACKGROUND: The mechanism underlying the beneficial cardiovascular effects of the incretin GLP‐1 (glucagon‐like peptide 1) and its analogues in humans is elusive. We hypothesized that activating receptors located on vascular smooth muscle cells to induce either peripheral or coronary vasodilatation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clarke, Sophie J., Giblett, Joel P., Yang, Lucy L., Hubsch, Annette, Zhao, Tian, Aetesam‐ur‐Rahman, Muhammad, West, Nick E. J., O'Sullivan, Michael, Figg, Nichola, Bennett, Martin, Wewer Albrechtsen, Nicolai J., Deacon, Carolyn F., Cheriyan, Joseph, Hoole, Stephen P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404441/ https://www.ncbi.nlm.nih.gov/pubmed/30571482 http://dx.doi.org/10.1161/JAHA.118.010321

Ejemplares similares

GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
por: Aetesam-ur-Rahman, Muhammad, et al.
Publicado: (2021)

Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion
por: Giblett, Joel P., et al.
Publicado: (2019)

Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner
por: Jepsen, Sara L., et al.
Publicado: (2021)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

Adenosine‐Induced Coronary Steal Is Observed in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction
por: Aetesam‐ur‐Rahman, Muhammad, et al.
Publicado: (2021)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
por: Tan, Tricia, et al.
Publicado: (2017)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory
por: Rahman, Haseeb, et al.
Publicado: (2019)

Identification of ADAM12 as a Novel Basigin Sheddase
por: Albrechtsen, Reidar, et al.
Publicado: (2019)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)

Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios
por: Aetesam‐ur‐Rahman, Muhammad, et al.
Publicado: (2022)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
por: Larger, Etienne, et al.
Publicado: (2016)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Stunning and Right Ventricular Dysfunction Is Induced by Coronary Balloon Occlusion and Rapid Pacing in Humans: Insights From Right Ventricular Conductance Catheter Studies
por: Axell, Richard G., et al.
Publicado: (2017)

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas
por: Kuhre, Rune E., et al.
Publicado: (2018)

Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome
por: Tesauro, Manfredi, et al.
Publicado: (2013)

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies
por: Giblett, Joel P., et al.
Publicado: (2016)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Individuals with type 2 diabetes have higher density of small intestinal neurotensin-expressing cells
por: Ferreira, Filipa P., et al.
Publicado: (2023)

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2022)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial
por: Zhao, Tian Xiao, et al.
Publicado: (2018)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Role of aldehyde dehydrogenase in hypoxic vasodilator effects of nitrite in rats and humans
por: Arif, Sayqa, et al.
Publicado: (2015)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Defining NASH from a Multi-Omics Systems Biology Perspective
por: Niu, Lili, et al.
Publicado: (2021)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9rkb1e452ttpre137bmtiicfi